Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels of ...

These findings may not be generalizable to uninsured patients with ovarian cancer, who face unique barriers to care compared with insured patients. Your study found no significant differences in ...

Adagene Inc. announced promising results from its Phase 1b/2 study of the CTLA-4 inhibitor ADG126 in patients with advanced microsatellite stable colorectal cancer (MSS CRC) without liver metastases.

WALTHAM, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people ...

WALTHAM, Mass., May 31, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for ...